natgillin/translations-raw huggingface dataset:
Please see how to use the pen in the Instructions for use manual.
Navodilo za uporabo peresnika si, prosimo, oglejte v priloženem navodilu.
Lot
Spol
STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled pen contains 1.61 mg parathyroid hormone corresponding to 14 doses.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN En napolnjen injekcijski peresnik vsebuje 1,61 mg obščitničnega hormona, kar ustreza 14 odmerkom.
Gastrointestinal disorders Very common
Zelo pogosti Hiperkalciurija
Each pre-filled pen contains 1.61 mg of parathyroid hormone as powder and 1.13 ml of solvent.
En napolnjen injekcijski peresnik vsebuje 1,61 mg obščitničničnega hormona v obliki praška in
• Take the daily injection • Store the pre-filled pen
• Vzamete dnevno injekcijo
The steps you have to go through with a new pre-filled pen:
Z novim napolnjenim injekcijskim peresnikom morate opraviti naslednje korake:
Antibodies to parathyroid hormone
Obščitnični hormon
Blood alkaline phosphatase increased Anorexia
Zvišana vrednost alkalne fosfataze v krvi
NAME OF THE MEDICINAL PRODUCT Preotact 100 micrograms powder and solvent for solution for injection in a pre-filled pen.
Preotact 100 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
What Preotact contains -The active substance is parathyroid hormone.
-Zdravilna učinkovina je obščitnični hormon.
This overview was last updated in 09-2014.
Pregled je bil nazadnje posodobljen 09-2014.
Further information on Eliquis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Nadaljnje informacije za zdravilo Eliquis so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It is available as tablets (2.5 mg, 5 mg).
Na voljo je v obliki tablet (2,5 in 5 mg).
Thrombin is central to the process of blood clotting.
Trombin ima osrednjo vlogo v postopku strjevanja krvi.
The European Medicines Agency decided that Eliquis' benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Eliquis večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Eliquis received a marketing authorisation valid throughout the EU on 18 May 2011.
Za zdravilo Eliquis je bilo 18. maja 2011 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Eliquis?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Eliquis?
As for all medicines, data on the use of Eliquis are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Eliquis stalno spremljajo.
Other information about Eliquis
Druge informacije o zdravilu Eliquis
For patients who have had a hip or knee replacement, treatment with Eliquis should be started 12 to 24 hours after the operation.
Pri bolnikih po kirurški zamenjavi kolka ali kolena je treba zdravljenje z zdravilom Eliquis začeti od 12 do 24 ur po operaciji.
For more information about using Eliquis, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Eliquis glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The recommended dose is one 2.5 mg tablet taken by mouth twice a day, usually for over one month (32 to 38 days) after a hip replacement or for 10 to 14 days after a knee replacement.
Priporočeni odmerek je ena 2,5-miligramska tableta; jemlje se dvakrat na dan peroralno, običajno več kot en mesec (od 32 do 38 dni) po kirurški zamenjavi kolka oziroma od 10 do 14 dni po kirurški zamenjavi kolena.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eliquis have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Eliquis upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What benefits of Eliquis have been shown in studies?
Kakšne koristi zdravila Eliquis so se pokazale v študijah?
It is used in patients who have one or more risk factors, such as having had a previous stroke, having high blood pressure, diabetes, heart failure or being 75 years old or over.
Uporablja se pri bolnikih z enim ali več dejavniki tveganja, kot so možganska kap v preteklosti, visok krvni tlak, sladkorna bolezen, srčno popuščanje ali starost 75 let ali več.
The most frequent side effects with Eliquis (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), haemorrhage (bleeding), haematoma (a collection of blood under the skin), contusion (bruising), nausea (feeling sick), low blood pressure (hypotension), epistaxis (nose bleeds), haematuria (blood in urine), low blood platelet counts (thrombocytopenia), blood tests showing alanine aminotransferase and gamma-glutamyltransferase increase and skin rash.
Najpogostejši neželeni učinki zdravila (opaženi pri 1 do 10 od 100 bolnikov) so anemija (nizko število rdečih krvnih celic), krvavitve, hematom (izliv krvi pod kožo), podplutbe, navzea (siljenje na bruhanje), nizek krvni tlak (hipotenzija), epistaksa (krvavitve iz nosu), hematurija (kri v urinu), nizko število trombocitov (trombocitopenija), krvni testi, ki kažejo zvišane ravni alanin-aminotransferaze in gama-glutamiltransferaze, ter kožni izpuščaji.
Why is Eliquis authorised in the EU?
Zakaj je bilo zdravilo Eliquis odobreno v EU?
The company that markets Eliquis will provide educational material for healthcare professionals expected to prescribe Eliquis that addresses the risk of bleeding during treatment.
Podjetje, ki trži zdravilo Eliquis, bo priskrbelo izobraževalno gradivo za zdravstvene delavce, ki bodo predvidoma predpisovali zdravilo Eliquis, in v njem opisalo tveganja za krvavitve med zdravljenjem.
An overview of Eliquis and why it is authorised in the EU
Pregled zdravila Eliquis in zakaj je odobreno v EU
Side effects reported with Eliquis are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Eliquis, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
Similarly, patients with atrial fibrillation are at high risk of clots forming in the heart, which can reach the brain where they can cause a stroke.
Podobno pri bolnikih z atrijsko fibrilacijo obstaja veliko tveganje za nastanek strdkov v srcu; ti strdki lahko pridejo v možgane in povzročijo možgansko kap.
In both studies, Eliquis was compared with enoxaparin (another medicine used to prevent blood clots).
V obeh študijah so zdravilo Eliquis primerjali z enoksaparinom (drugim zdravilom za preprečevanje krvnih strdkov).
Some of these side effects are not seen with all the uses of Eliquis.
Nekateri od teh neželenih učinkov se ne pojavijo pri vseh načinih uporabe zdravila Eliquis.
The medicine must also not be used in patients with conditions putting them at risk of major bleeding, such as an ulcer in the gut, or in patients being treated with other anticoagulant medicines except in specific circumstances (see summary of product characteristics).
Zdravilo se prav tako ne sme uporabljati pri bolnikih z boleznimi, zaradi katerih pri njih obstaja tveganje za večje krvavitve, kot so razjede v črevesju, ali bolnikih, ki prejemajo druga antikoagulacijska zdravila, razen v posebnih okoliščinah (glejte povzetek glavnih značilnosti zdravila).
What is Eliquis and what is it used for?
Kaj je zdravilo Eliquis in za kaj se uporablja?
Eliquis must not be used in patients who are actively bleeding, or who have liver disease which leads to problems with blood clotting and an increased risk of bleeding.
Zdravilo Eliquis se ne sme uporabljati pri bolnikih z aktivno krvavitvijo ali boleznijo jeter, ki povzroča težave s strjevanjem krvi in večje tveganje za krvavitve.
What are the risks associated with Eliquis?
Kakšna tveganja so povezana z zdravilom Eliquis?
Eliquis was effective at preventing blood clots in the veins following a hip or knee replacement in two main studies involving a total of 8,464 patients.
Zdravilo Eliquis je bilo učinkovito pri preprečevanju krvnih strdkov v venah po kirurški zamenjavi kolka ali kolena v dveh glavnih študijah s skupno 8 464 bolniki.
It is also used in adults to treat deep vein thrombosis (blood clot in a deep vein, usually in the leg) and pulmonary embolism (clot in a blood vessel supplying the lungs), and to prevent their reoccurrence.
Uporablja se tudi pri odraslih za zdravljenje globoke venske tromboze (krvnega strdka v globoki veni, običajno v nogi) in pljučne embolije (strdka v krvni žili, ki oskrbuje pljuča) ter za preprečevanje njune ponovne pojavitve.
For the treatment of deep vein thrombosis and pulmonary embolism, the recommended dose is 10 mg twice a day for the first week, followed by 5 mg twice a day for at least 3 months.
Za zdravljenje globoke venske tromboze in pljučne embolije je priporočeni odmerek 10 mg dvakrat na dan prvi teden, nato pa 5 mg dvakrat na dan vsaj tri mesece.
Eliquis was also shown to be effective in preventing strokes and arterial blood clots in patients with atrial fibrillation in two main studies: the first (in 18,201 patients) compared Eliquis with another medicine, warfarin, while the second (in 5,598 patients) compared Eliquis with aspirin.
Poleg tega se je v dveh glavnih študijah zdravilo Eliquis izkazalo za učinkovito pri preprečevanju možganskih kapi in krvnih strdkov v arterijah pri bolnikih z atrijsko fibrilacijo: v prvi (z 18 201 bolnikom) so zdravilo Eliquis primerjali z drugim zdravilom, varfarinom, v drugi (s 5 598 bolniki) pa so zdravilo Eliquis primerjali z acetilsalicilno kislino (aspirinom).
In patients undergoing a knee replacement, the corresponding numbers were 15% (147 out of 976) for Eliquis compared with 24% (243 out of 997) for enoxaparin.
Pri bolnikih po kirurški zamenjavi kolena sta bila ta deleža 15 % (147 od 976) bolnikov, ki so jemali zdravilo Eliquis, in 24 % (243 od 997) bolnikov, ki so jemali enoksaparin.
In the prevention study in 2,482 patients, Eliquis was compared with placebo (a dummy treatment) and its effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during treatment.
V študiji preprečevanja z 2 482 bolniki so zdravilo Eliquis primerjali s placebom (zdravilom brez učinkovine), njegovo učinkovitost pa so merili s številom bolnikov, ki so imeli težave zaradi strdkov v venah ali so med zdravljenjem iz katerega koli vzroka umrli.
For patients with atrial fibrillation at risk of stroke or blood clots, the recommended dose is 5 mg taken twice a day.
Pri bolnikih z atrijsko fibrilacijo, pri katerih obstaja tveganje za možgansko kap ali krvne strdke, je priporočeni odmerek 5 mg dvakrat na dan.
By blocking factor Xa, it reduces the levels of thrombin in the blood, which reduces the risk of blood clots forming in the arteries and veins.
Z zaviranjem faktorja Xa zdravilo Eliquis zmanjšuje količino trombina v krvi in s tem zmanjšuje tveganje za nastanek krvnih strdkov v arterijah in venah.
Eliquis contains the active substance apixaban.
Zdravilo Eliquis vsebuje učinkovino apiksaban.
To prevent deep vein thrombosis and pulmonary embolism from reoccurring, the recommended dose is 2.5 mg twice a day.
Za preprečevanje ponovne pojavitve globoke venske tromboze in pljučne embolije je priporočeni odmerek 2,5 mg dvakrat na dan.
Eliquis was also effective at treating deep vein thrombosis and pulmonary embolism and preventing their reoccurrence in two main studies.
Zdravilo Eliquis je bilo v dveh glavnih študijah tudi učinkovito pri zdravljenju globoke venske tromboze in pljučne embolije ter preprečevanju njune ponovne pojavitve.
The medicine's effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during the treatment period.
Učinkovitost zdravila so merili s številom bolnikov, ki so imeli težave zaradi strdkov v venah ali so med obdobjem zdravljenja iz katerega koli vzroka umrli.
2.3% of patients taking Eliquis (2.5 mg twice a day) experienced a clot or died, compared with 9.3% of patients taking placebo.
Do nastanka strdka ali smrti je prišlo pri 2,3 % bolnikov, ki so prejemali zdravilo Eliquis (2,5 mg dvakrat na dan), in pri 9,3 % bolnikov, ki so jemali placebo.
The main measures of effectiveness were based on the number of strokes or clotting events that occurred during treatment.
Glavno merilo učinkovitosti je temeljilo na številu možganskih kapi ali težav zaradi strdkov, ki so se pojavile med zdravljenjem.
The yearly rates in the second study were 1.6% for patients taking Eliquis and 3.6% for patients taking aspirin.
V drugi študiji sta bili ti letni stopnji 1,6 % bolnikov, ki so prejemali zdravilo Eliquis, in 3,6 % bolnikov, ki so jemali acetilsalicilno kislino.
The active substance in Eliquis, apixaban, is a ‘factor Xa inhibitor'.
Učinkovina v zdravilu Eliquis, apiksaban, je zaviralec faktorja Xa.
In patients undergoing a hip replacement, 1.4% of the patients who completed treatment with Eliquis (27 out of 1,949) had a clotting event or died from any cause, compared with 3.9% (74 out of 1,917) of the patients taking enoxaparin.
Pri bolnikih po kirurški zamenjavi kolka so se pri 1,4 % (27 od 1 949) bolnikov, ki so zaključili zdravljenje z zdravilom Eliquis, pojavile težave zaradi strdkov ali pa so ti bolniki iz katerega koli vzroka umrli, medtem ko je bil pri bolnikih, ki so jemali enoksaparin, ta delež 3,9 % (74 od 1 917).
Eliquis is a medicine used to prevent venous thromboembolism (blood clots in the veins) in adults following a hip or knee replacement operation.
Zdravilo Eliquis se uporablja za preprečevanje venske trombembolije (krvnih strdkov v venah) pri odraslih po kirurški zamenjavi kolka ali kolena.
For the full list of side effects and restrictions with Eliquis, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Eliquis glejte navodilo za uporabo.
Additionally, Eliquis is used to prevent stroke (caused by blood clots in the brain) and blood clots in other organs in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).
Zdravilo Eliquis se uporablja tudi za preprečevanje možganske kapi (ki jo povzročijo krvni strdki v možganih) in krvnih strdkov v drugih organih pri odraslih z atrijsko fibrilacijo (hitrim in nepravilnim krčenjem preddvorov srca).
How does Eliquis work?
Kako zdravilo Eliquis deluje?
How is Eliquis used?
Kako se zdravilo Eliquis uporablja?
In the study comparing Eliquis with warfarin, 1.3 % of the patients taking Eliquis had a stroke or clotting event every year compared with 1.6% of the patients taking warfarin.
V študiji, v kateri so zdravilo Eliquis primerjali z varfarinom, je do možganske kapi ali težav zaradi strdkov vsako leto prišlo pri 1,3 % bolnikov, ki so prejemali zdravilo Eliquis, in 1,6 % bolnikov, ki so jemali varfarin.
Eliquis can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Eliquis je le na recept.
Patients undergoing hip or knee replacement surgery, who have had a recent trauma, or are confined to bed are at a high risk of blood clots forming in the veins, which can be dangerous and even fatal if they move to another part of the body such as the lungs.
Pri bolnikih, ki so prestali kirurško zamenjavo kolka ali kolena, so pred kratkim utrpeli poškodbo ali morajo ležati, obstaja veliko tveganje za nastanek krvnih strdkov v venah.
2.3% of patients treated with Eliquis had a clot or died, compared with 2.7% of patients treated with enoxaparin plus warfarin, showing that Eliquis was as effective as the comparator treatment.
Do nastanka strdka ali smrti je prišlo pri 2,3 % bolnikov, ki so prejemali zdravilo Eliquis, in pri 2,7 % bolnikov, ki so prejemali enoksaparin in varfarin.
In the treatment study conducted in 5,395 patients, Eliquis was compared with enoxaparin followed by warfarin; the main measure of effectiveness was based on the number of patients who either had blood clots in the veins of the legs or lungs or died because of this during the treatment period.
V študiji zdravljenja s 5 395 bolniki so zdravilo Eliquis primerjali z enoksaparinom in nato še varfarinom.
This summary was last updated in 01-2018.
Povzetek je bil nazadnje posodobljen 01-2018.
The European Commission granted a marketing authorisation valid throughout the European Union for Faslodex on 10 March 2004.
Evropska komisija je dovoljenje za promet z zdravilom Faslodex, veljavno po vsej Evropski uniji, izdala 10. marca 2004.
The full EPAR for Faslodex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Faslodex je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Faslodex.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Faslodex.
What measures are being taken to ensure the safe and effective use of Faslodex?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Faslodex?
The European Medicines Agency concluded that the benefits seen in studies with Faslodex are greater than its risks and recommended that it be given marketing authorisation.
Evropska agencija za zdravila je sklenila, da so v študijah ugotovljene koristi zdravila Faslodex večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Faslodex have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Faslodex upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Faslodex is available as a solution for injection in prefilled syringes (250 mg).
Zdravilo Faslodex je na voljo v obliki raztopine za injiciranje v napolnjeni injekcijski brizgi (250 mg).
Faslodex is an anti-oestrogen medicine used to treat advanced or metastatic breast cancer (cancer that has spread to other parts of the body) in the following patients:
Faslodex je antiestrogensko zdravilo za zdravljenje raka, ki se uporablja pri napredovalem ali metastatskem raku dojke (raku, ki se je razširil v druge dele telesa) pri naslednjih bolnicah:
The dose is given as two injections, each given into the muscle of one buttock over one to two minutes.
Odmerek se daje z dvema injekcijama v mišico, po eno injekcijo v vsako stran zadnjice, v eni do dveh minutah.
As a result, the cancer cells are not stimulated to grow by oestrogen and this slows down the growth of the tumour.
Estrogen zato celic raka ne spodbuja k rasti, kar upočasni rast tumorja.
Other information about Faslodex
Druge informacije o zdravilu Faslodex
In women with this type of breast cancer, Faslodex is used in combination with palbociclib (another cancer medicine).
Pri ženskah s to vrsto raka dojke se zdravilo Faslodex uporablja v kombinaciji s palbociklibom (drugim zdravilom za zdravljenje raka).
The recommended dose is 500 mg given once a month, with an additional 500-mg dose two weeks after the first dose.
Priporočeni odmerek je 500 mg v enomesečnih presledkih ter dodaten 500-miligramski odmerek, uporabljen dva tedna po začetnem odmerku.
For more information about treatment with Faslodex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Faslodex preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Faslodex must not be used in women who are pregnant or breast-feeding, or in patients who have severe liver disease.
Zdravila Faslodex ne smejo uporabljati nosečnice ali doječe matere ali bolnice, ki imajo huda obolenja jeter.
It blocks the receptors for oestrogen on cells and causes the number of oestrogen receptors to fall.
Zavira receptorje za estrogen na celicah in povzroča zmanjšanje števila estrogenskih receptorjev.
The most common serious side effects were low levels of white and red blood cells, low levels of blood platelets, infections, increased liver enzyme levels and tiredness.
Najpogostejši resni neželeni učinki so bili nizko število belih in rdečih krvnih celic, nizko število trombocitov, okužbe, povečane ravni jetrnih encimov in utrujenost.
• postmenopausal women with a type of breast cancer known as ‘oestrogen-receptor positive cancer' who have not previously had hormonal treatment, or whose cancer had come back after treatment with another anti-oestrogen;
• ženskah po menopavzi z vrsto raka dojke, imenovano „rak s pozitivnimi estrogenskimi receptorji“, ki predhodno niso bile zdravljene s hormonskim zdravljenjem ali pri katerih se je rak ponovil po zdravljenju z drugim antiestrogenom;
The active substance in Faslodex, fulvestrant, is an anti-oestrogen.
Zdravilna učinkovina v zdravilu Faslodex, fulvestrant, je antiestrogen.
For practical information about using Faslodex, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Faslodex naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Faslodex, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Faslodex glejte navodilo za uporabo.
It is not intended to provide practical advice on how to use Faslodex.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What is Faslodex and what is it used for?
Kaj je zdravilo Faslodex in za kaj se uporablja?
Most types of breast cancer are stimulated to grow when the hormone oestrogen attaches to targets (receptors) on cancer cells.
Rast večine vrst raka dojke spodbuja vezava hormona estrogena na tarče (receptorje) na celicah raka.
Five main studies showed that Faslodex is effective at prolonging the length of time patients live without their disease getting worse.
Pet glavnih študij je pokazalo, da je zdravilo Faslodex učinkovito pri podaljševanju časa preživetja bolnic brez poslabšanja bolezni.
What benefits of Faslodex have been shown in studies?
Kakšne koristi je zdravilo Faslodex izkazalo v študijah?
Why is Faslodex approved?
Zakaj je bilo zdravilo Faslodex odobreno?
What are the risks associated with Faslodex?
Kakšna tveganja so povezana z zdravilom Faslodex?
When Faslodex is used on its own, the most common side effects (seen in more than 1 patient in 10) are injection-site reactions (such as pain or inflammation), weakness, nausea (feeling sick) and increased liver enzyme levels in the blood (a sign of liver problems).
Kadar se zdravilo Faslodex uporablja kot samostojno zdravilo, so najpogostejši neželeni učinki (ki so se pojavili pri več kot 1 bolnici od 10) reakcije na mestu injiciranja (npr. bolečine ali vnetje), šibkost, navzeja (siljenje na bruhanje) in povečana raven jetrnih encimov v krvi (znak težav z jetri).
The fourth study, in 462 women with advanced or metastatic breast cancer who had not been treated with hormonal therapy, showed that women treated with Faslodex (500 mg once a month) lived for an average of 16.6 months without their disease getting worse, compared with 13.8 months for women given anastrozole.
Četrta študija s 462 ženskami z napredovalim ali metastatskim rakom dojke, ki niso bile zdravljene s hormonskim zdravljenjem, je pokazala, da so ženske, ki so bile zdravljene z zdravilom Faslodex (v odmerku 500 mg enkrat na mesec), brez poslabšanja bolezni povprečno preživele 16,6 meseca, ženske, ki so prejemale anastrozol, pa 13,8 meseca.